- British Pharmacopoeia Volume III
- Formulated Preparations: Specific Monographs
Adrenaline and Cocaine Intranasal Solution / Epinephrine and Cocaine Intranasal Solution |
Note: Adrenaline and Cocaine Intranasal Solution is not currently licensed in the United Kingdom.
Adrenoceptor agonist + local anaesthetic.
Adrenaline and Cocaine Intranasal Solution contains Adrenaline Acid Tartrate and Cocaine Hydrochloride in a suitable vehicle.
The intranasal solution complies with the requirements stated under Nasal Preparations, the requirements stated under Unlicensed Medicines and with the following requirements.
95.0 to 105.0% of the stated amount.
95.0 to 105.0% of the stated amount.
A. In the Assay for adrenaline, the principal peak in the chromatogram obtained with solution (1) has the same retention time as that in the chromatogram obtained with solution (2).
B. In the Assay for cocaine hydrochloride, the principal peak in the chromatogram obtained with solution (1) has the same retention time as that in the chromatogram obtained with solution (2).
C. To 10 ml of the intranasal solution add 2 mL of a 10% w/v solution of disodium hydrogen orthophosphate and sufficient iodinated potassium iodide solution to produce a brown colour and remove excess iodine by adding 0.1m sodium thiosulfate drop wise. A red colour is produced.
D. Yields reaction A characteristic of chlorides, Appendix VI.
pH, 2.0 to 4.0, Appendix V L.
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
(1) Dilute a volume of the intranasal solution with sufficient mobile phase to produce a solution containing 0.04% w/v of Cocaine Hydrochloride.
(2) 0.0008% w/v of benzoylecgonine hydrate in the mobile phase.
(3) 0.0008% w/v of benzoic acid in the mobile phase.
(4) 0.0008% w/v of each of benzoylecgonine hydrate and benzoic acid in solution (1).
(a) Use a stainless steel column (25 cm × 4.6 mm) packed with octadecylsilyl silica gel for chromatography (10 µm) (Partisil 10 ODS is suitable).
(b) Use isocratic elution and the mobile phase described below.
(c) Use a flow rate of 2 mL per minute.
(d) Use an ambient column temperature.
(e) Use a detection wavelength of 240 nm.
(f) Inject 20 µL of each solution.
1 volume of 9m perchloric acid, 35 volumes of methanol and 64 volumes of water.
The test is not valid unless, in the chromatogram obtained with solution (4), the resolution factor between the peaks corresponding to benzoylecgonine and benzoic acid is at least 2.0.
In the chromatogram obtained with solution (1):
the area of any peak corresponding to benzoylecgonine is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (2%);
the area of any peak corresponding to benzoic acid is not greater than the area of the principal peak in the chromatogram obtained with solution (3) (2%).
The total impurity content is not greater than 2%.
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
(1) Dilute a suitable volume of the intranasal solution with sufficient mobile phase to produce a solution containing the equivalent of 0.011% w/v of adrenaline.
(2) 0.02% w/v of adrenaline acid tartrate BPCRS in the mobile phase.
(3) 0.02% w/v of adrenaline acid tartrate BPCRS and 0.02% w/v of noradrenaline acid tartrate in the mobile phase.
(a) Use a stainless steel column (10 cm × 4.6 mm) packed with end-capped octadecylsilyl silica gel for chromatography (5 µm) (Nucleosil C18 is suitable).
(b) Use isocratic elution and the mobile phase described below.
(c) Use a flow rate of 2 mL per minute.
(d) Use an ambient column temperature.
(e) Use a detection wavelength of 205 nm.
(f) Inject 20 µL of each solution.
Dissolve 4.0 g of tetramethylammonium hydrogen sulfate, 1.1 g of sodium heptanesulfonate and 2 mL of 0.1m disodium edetate in a mixture of 950 mL of water and 50 mL of methanol and adjust the pH to 3.5 with 1m sodium hydroxide.
The assay is not valid unless, in the chromatogram obtained with solution (3), the resolution factor between the two principal peaks is at least 2.0.
Calculate the content of C9H13NO3 in the intranasal solution from the chromatograms obtained and using the declared content of C9H13NO3 in adrenaline acid tartrate BPCRS.
Carry out the method for liquid chromatography, Appendix III D, using the following solutions.
(1) Dilute a volume of the intranasal solution containing 40 mg of Cocaine Hydrochloride with sufficient water to produce 100 mL.
(2) 0.04% w/v of cocaine hydrochloride BPCRS in water.
(3) 0.0008% w/v of each of benzoylecgonine hydrate and benzoic acid in solution (1).
(a) Use a stainless steel column (25 cm × 4.6 mm) packed with octadecylsilyl silica gel for chromatography (10 µm) (Partisil 10 ODS is suitable).
(b) Use isocratic elution and the mobile phase described below.
(c) Use a flow rate of 2 mL per minute.
(d) Use an ambient column temperature.
(e) Use a detection wavelength of 240 nm.
(f) Inject 20 µL of each solution.
1 volume of 9m perchloric acid, 35 volumes of methanol and 64 volumes of water.
The test is not valid unless, in the chromatogram obtained with solution (3), the resolution factor between the peaks corresponding to benzoylecgonine and benzoic acid is at least 2.0.
Calculate the content of C17H21NO4,HCl in the intranasal solution from the chromatograms obtained and using the declared content of C17H21NO4,HCl in cocaine hydrochloride BPCRS.
Adrenaline and Cocaine Intranasal Solution should be protected from light.
The quantity of adrenaline acid tartrate is stated in terms of the equivalent amount of adrenaline (epinephrine).
The impurities limited by the requirements of this monograph include:
1. Benzoylecgonine,
2. Benzoic acid.